Israeli natural products chemist Raphael Mechoulam has never smoked a joint, but he has spent decades studying the chemistry and pharmacology of cannabinoids and was the first to isolate delta-9 tetrahydrocannabinol (THC) in its pure form in the 1960s.
Because of Mechoulam’s contributions to cannabis research over the years, he is often referred to as the Father of Cannabis Research.
Next month, Mechoulam will be the recipient of an award in recognition of his revolutionary research and contributions to the understanding of the cannabis plant.
The Oakland-based Arcview Group announced on Friday that they will be honoring Mechoulam with a lifetime achievement award and a $10,000 research grant at the Arcview Investor Forum: The Evolution of Cannabis: 2020 at 7:00 p.m. on Thursday, October 3 in New York.
“Cannabis research has never been more critical to the future of our industry, especially as the federal government begins processing dozens of pending applications for the steps necessary to improve access to marijuana research,” said Arcview Group co-founder and CEO Troy Dayton. “As the first person to synthesize THC, identify the endocannabinoid system and illustrate the medicinal properties of cannabis, no one is more deserving than Raphael of our Lifetime Achievement Award. We can’t wait to see what he uncovers next.”
The award will be dubbed the Arcview Raphael Mechoulam Lifetime Achievement Award for future recipients to preserve and continue to honor Mechoulam’s work.
In addition to recognizing Mechoulam for his contributions to cannabinoid research, the Arcview Investor Forum will bring together fund managers, CEOs, and key investors from some of the biggest cannabis companies in the industry.
Seven cannabis companies have been selected by Arcview Investor Network members to present to investors in a Shark Tank-style format during the forum.
Network members who are interested in attending the Investor Forum may register at the Arcview website.
